Cipla's performance was impacted by several one-offs during the quarter. Revenue and net profit were almost, while EBITDA and margins grew by 24% and 417bps YoY.US and Europe were the only regions that reported a growth of 67% and 50% YoY. The domestic performance was impacted by the disruption in trade generics business while Emerging markets...